Nuwellis, Inc. To Report Fourth Quarter and Full Year 2024 Financial Results on March 11, 2025
Nuwellis (Nasdaq: NUWE), a commercial-stage medical technology company specializing in fluid overload solutions, has announced it will release its Q4 and full year 2024 financial results on March 11, 2025. The company will host a conference call and webcast at 9:00 AM ET to discuss the results and provide a business update.
Investors can access the live webcast through the company's investor relations website at ir.nuwellis.com, or join the conference call by dialing 1-800-245-3047 (U.S) or 1-203-518-9765 (international) using conference ID: NUWEQ4. An audio archive will be available after the call on the company's investor website.
Nuwellis (Nasdaq: NUWE), un'azienda tecnologica medica in fase commerciale specializzata in soluzioni per il sovraccarico di fluidi, ha annunciato che rilascerà i suoi risultati finanziari del Q4 e dell'intero anno 2024 il 11 marzo 2025. L'azienda ospiterà una conferenza telefonica e un webcast alle 9:00 AM ET per discutere i risultati e fornire un aggiornamento aziendale.
Gli investitori possono accedere al webcast dal vivo attraverso il sito web delle relazioni con gli investitori dell'azienda all'indirizzo ir.nuwellis.com, oppure partecipare alla conferenza telefonica componendo il numero 1-800-245-3047 (U.S) o 1-203-518-9765 (internazionale) utilizzando l'ID conferenza: NUWEQ4. Un archivio audio sarà disponibile dopo la chiamata sul sito web degli investitori dell'azienda.
Nuwellis (Nasdaq: NUWE), una empresa de tecnología médica en etapa comercial especializada en soluciones para la sobrecarga de fluidos, ha anunciado que publicará sus resultados financieros del Q4 y del año completo 2024 el 11 de marzo de 2025. La empresa llevará a cabo una conferencia telefónica y un webcast a las 9:00 AM ET para discutir los resultados y proporcionar una actualización del negocio.
Los inversores pueden acceder al webcast en vivo a través del sitio web de relaciones con inversores de la empresa en ir.nuwellis.com, o unirse a la conferencia telefónica marcando el 1-800-245-3047 (EE. UU.) o 1-203-518-9765 (internacional) utilizando el ID de conferencia: NUWEQ4. Un archivo de audio estará disponible después de la llamada en el sitio web de inversores de la empresa.
Nuwellis (Nasdaq: NUWE)는 체액 과다 솔루션을 전문으로 하는 상업 단계의 의료 기술 회사로, 2024년 4분기 및 연간 재무 결과를 2025년 3월 11일에 발표할 것이라고 발표했습니다. 회사는 오전 9시 ET에 결과를 논의하고 비즈니스 업데이트를 제공하는 컨퍼런스 콜 및 웹캐스트를 개최합니다.
투자자들은 ir.nuwellis.com에서 회사의 투자자 관계 웹사이트를 통해 라이브 웹캐스트에 접속할 수 있으며, 컨퍼런스 ID: NUWEQ4를 사용하여 1-800-245-3047 (미국) 또는 1-203-518-9765 (국제)로 전화를 걸어 컨퍼런스 콜에 참여할 수 있습니다. 통화 후에는 회사의 투자자 웹사이트에서 오디오 아카이브를 이용할 수 있습니다.
Nuwellis (Nasdaq: NUWE), une entreprise de technologie médicale en phase commerciale spécialisée dans les solutions de surcharge liquidienne, a annoncé qu'elle publiera ses résultats financiers du Q4 et de l'année entière 2024 le 11 mars 2025. L'entreprise organisera une conférence téléphonique et un webcast à 9h00 ET pour discuter des résultats et fournir une mise à jour sur l'entreprise.
Les investisseurs peuvent accéder au webcast en direct via le site web des relations investisseurs de l'entreprise à l'adresse ir.nuwellis.com, ou rejoindre la conférence téléphonique en composant le 1-800-245-3047 (États-Unis) ou le 1-203-518-9765 (international) en utilisant l'ID de conférence : NUWEQ4. Un enregistrement audio sera disponible après l'appel sur le site web des investisseurs de l'entreprise.
Nuwellis (Nasdaq: NUWE), ein Unternehmen für Medizintechnologie in der kommerziellen Phase, das sich auf Lösungen zur Flüssigkeitsüberlastung spezialisiert hat, hat angekündigt, dass es seine finanziellen Ergebnisse für das Q4 und das gesamte Jahr 2024 am 11. März 2025 veröffentlichen wird. Das Unternehmen wird um 9:00 Uhr ET eine Telefonkonferenz und einen Webcast abhalten, um die Ergebnisse zu besprechen und ein Unternehmensupdate zu geben.
Investoren können über die Investor-Relations-Website des Unternehmens unter ir.nuwellis.com auf den Live-Webcast zugreifen oder an der Telefonkonferenz teilnehmen, indem sie 1-800-245-3047 (USA) oder 1-203-518-9765 (international) wählen und die Konferenz-ID: NUWEQ4 verwenden. Ein Audioarchiv wird nach dem Anruf auf der Investor-Website des Unternehmens verfügbar sein.
- None.
- None.
MINNEAPOLIS, Feb. 18, 2025 (GLOBE NEWSWIRE) -- Nuwellis, Inc. (Nasdaq: NUWE), a commercial-stage medical technology company focused on transforming the lives of people with fluid overload, today announced that it will release financial results for the fourth quarter and full year 2024 on March 11, 2025. Nuwellis will host a conference call and webcast at 9:00 AM ET to discuss its financial results and provide a general business update.
To access the live webcast, please visit the Investors page of the Nuwellis website at https://ir.nuwellis.com. Alternatively, you may access the live conference call by dialing 1-800-245-3047 (U.S) or 1-203-518-9765 (international) and using the conference ID: NUWEQ4. An audio archive of the webcast will be available following the call on the Investors page at https://ir.nuwellis.com.
About Nuwellis
Nuwellis, Inc. (Nasdaq: NUWE) is a commercial-stage medical technology company dedicated to transforming the lives of patients suffering from fluid overload through science, collaboration, and innovation. The company is focused on commercializing the Aquadex SmartFlow® system for ultrafiltration therapy. Nuwellis is headquartered in Minneapolis, with a wholly owned subsidiary in Ireland. For more information visit ir.nuwellis.com or visit us on LinkedIn or X.
About the Aquadex SmartFlow® System
The Aquadex SmartFlow system delivers clinically proven therapy using a simple, flexible and smart method of removing excess fluid from patients suffering from hypervolemia (fluid overload). The Aquadex SmartFlow system is indicated for temporary (up to 8 hours) or extended (longer than 8 hours in patients who require hospitalization) use in adult and pediatric patients weighing 20 kg or more whose fluid overload is unresponsive to medical management, including diuretics. All treatments must be administered by a health care provider, within an outpatient or inpatient clinical setting, under physician prescription, both having received training in extracorporeal therapies.
CONTACTS
INVESTORS:
Vivian Cervantes
Gilmartin Group LLC
ir@nuwellis.com
FAQ
When will Nuwellis (NUWE) release its Q4 and full year 2024 earnings?
What time is the Nuwellis (NUWE) Q4 2024 earnings call?
How can investors access the Nuwellis (NUWE) Q4 2024 earnings call?
Where can I find the replay of Nuwellis (NUWE) Q4 2024 earnings call?
